• Sale of assets related to the Flow Cytometry & Imaging (FCI) business.
• The acquisition will expand Cytek’s product portfolio to include imaging and menu-based application-driven flow cytometry to provide complete cell analysis solutions to its customers
• The transaction is in line with DiaSorin’s strategic priorities communicated to the market following the acquisition of Luminex
• Employees involved in commercial, operational, R&D and support functions are expected to transfer to Cytek

SALUGGIA, Italy and FREMONT, Calif., February 13, 2023 (GLOBE NEWSWIRE) — DiaSorin (FTSE-MIB: DIA) and Cytek Biosciences, Inc. CTKB announced today that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to its Flow Cytometry & Imaging (FCI) business. The sale is expected to be completed within 30 days, subject to customary closing conditions.

Acquired from Luminex in October 2018, the FCI business unit is based on both conventional flow cytometry and image-based flow cytometry instrumentation, providing insight into all facets of cellular phenotypes and morphology. FCI’s business unit includes dedicated commercial, operational, research and development and support staff.

An existing installed base of more than 7,000 instruments will be under the Cytek umbrella after the acquisition, expanding the company’s global commercial footprint.

The decision to sell the FCI business unit to Cytek is in line with strategic priorities communicated to investors during Capital Market Day in December 2021.

“We are currently working on several projects that will allow DiaSorin to continue growing over the next few years and strengthen our positioning as a specialty company,” commented Angelo Rago, President of Luminex. “To achieve this, we need to be extremely focused for our future and that is why we have decided to sell the Flow Cytometry & Imaging business unit to a dedicated, leading player in the industry. We are confident that Cytek will be able to…